Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLM NASDAQ:ELUT NASDAQ:MYNZ NASDAQ:SCYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$18.59-1.5%$16.94$3.66▼$42.12$39.99M1.4431,058 shs13,124 shsELUTElutia$0.93-0.3%$1.01$0.50▼$2.50$39.79M0.8597,751 shs67,747 shsMYNZMainz Biomed$1.08-2.7%$1.97$0.55▼$4.43$9.79M0.31371,589 shs607,386 shsSCYXSCYNEXIS$3.73-5.8%$4.56$3.68▼$10.48$37.04M1.1179,247 shs90,940 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics-1.46%+0.35%-9.34%+38.95%+211.31%ELUTElutia-0.27%-2.11%-5.21%-13.08%-54.41%MYNZMainz Biomed-2.63%-6.72%-25.50%+118.68%-46.63%SCYXSCYNEXIS-5.81%-12.65%-3.62%-54.29%-36.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$18.59-1.5%$16.94$3.66▼$42.12$39.99M1.4431,058 shs13,124 shsELUTElutia$0.93-0.3%$1.01$0.50▼$2.50$39.79M0.8597,751 shs67,747 shsMYNZMainz Biomed$1.08-2.7%$1.97$0.55▼$4.43$9.79M0.31371,589 shs607,386 shsSCYXSCYNEXIS$3.73-5.8%$4.56$3.68▼$10.48$37.04M1.1179,247 shs90,940 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics-1.46%+0.35%-9.34%+38.95%+211.31%ELUTElutia-0.27%-2.11%-5.21%-13.08%-54.41%MYNZMainz Biomed-2.63%-6.72%-25.50%+118.68%-46.63%SCYXSCYNEXIS-5.81%-12.65%-3.62%-54.29%-36.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMApollomics 1.00SellN/AN/AELUTElutia 2.00Hold$6.00545.16% UpsideMYNZMainz Biomed 1.50ReduceN/AN/ASCYXSCYNEXIS 2.00Hold$24.00543.43% UpsideCurrent Analyst Ratings BreakdownLatest MYNZ, ELUT, APLM, and SCYX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026ELUTElutia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)7/13/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/10/2026SCYXSCYNEXIS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/7/2026ELUTElutia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)6/26/2026SCYXSCYNEXIS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/23/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/17/2026ELUTElutia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)6/12/2026SCYXSCYNEXIS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/4/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMApollomics$8.50M4.80N/AN/A($2.89) per share-6.43ELUTElutia$12.29M3.24N/AN/A$0.65 per share1.43MYNZMainz Biomed$659.94K14.83N/AN/A$2.61 per share0.41SCYXSCYNEXIS$20.60M1.80N/AN/A$9.07 per share0.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMApollomics-$10.94MN/AN/AN/AN/AN/AN/AN/A9/24/2026 (Estimated)ELUTElutia$53.38M$0.861.08N/AN/A312.09%N/A-53.97%8/14/2026 (Estimated)MYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ASCYXSCYNEXIS-$8.61M-$3.84N/AN/AN/A-41.79%-57.16%-39.48%8/12/2026 (Estimated)Latest MYNZ, ELUT, APLM, and SCYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2026Q2 2026ELUTElutia-$0.15N/AN/AN/A$2.90 millionN/A8/12/2026Q2 2026SCYXSCYNEXIS-$0.5067N/AN/AN/A$0.08 millionN/A5/14/2026Q1 2026ELUTElutia-$0.15-$0.17-$0.02-$0.17$3.00 million$3.11 million5/11/2026Q1 2026SCYXSCYNEXIS-$0.10-$0.42-$0.32-$3.36$0.08 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMApollomicsN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLMApollomicsN/A0.960.96ELUTElutiaN/A2.051.94MYNZMainz Biomed0.440.520.43SCYXSCYNEXISN/A3.943.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMApollomics19.13%ELUTElutia74.03%MYNZMainz BiomedN/ASCYXSCYNEXIS54.37%Insider OwnershipCompanyInsider OwnershipAPLMApollomicsN/AELUTElutia17.80%MYNZMainz Biomed18.20%SCYXSCYNEXIS4.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMApollomics452.20 millionN/ANot OptionableELUTElutia18042.78 million35.17 millionNot OptionableMYNZMainz Biomed309.06 million7.41 millionNot OptionableSCYXSCYNEXIS609.93 million9.52 millionOptionableMYNZ, ELUT, APLM, and SCYX HeadlinesRecent News About These CompaniesSCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)June 30, 2026 | globenewswire.comSCYNEXIS Shareholders Approve Governance and Equity Plan ChangesJune 26, 2026 | tipranks.comSCYNEXIS Inc.June 24, 2026 | marketwatch.comSCYNEXIS Announces One-for-Eight Reverse Stock SplitMay 22, 2026 | globenewswire.comSCYNEXIS (SCYX) price target increased by 20.73% to 4.28May 14, 2026 | msn.comSCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 11, 2026 | globenewswire.comSCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 6, 2026 | globenewswire.comSCYNEXIS Raises $40 Million in Strategic Private PlacementApril 19, 2026 | theglobeandmail.comSCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics TranscriptMarch 31, 2026 | seekingalpha.comSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney ...March 31, 2026 | markets.businessinsider.comWhy did SCYX stock jump 10% in pre-market today?March 31, 2026 | msn.comPoxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 MillionMarch 31, 2026 | businesswire.comSCYNEXIS Announces $40.0 Million Private PlacementMarch 31, 2026 | globenewswire.comSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)March 31, 2026 | globenewswire.comSCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal TherapyMarch 12, 2026 | insidermonkey.comScynexis: Q4 Earnings SnapshotMarch 4, 2026 | wiltonbulletin.comWSCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate UpdateMarch 4, 2026 | globenewswire.comSCYNEXIS, Inc. Initiates Phase 1 Trial for Intravenous Antifungal SCY-247 Following FDA DesignationsFebruary 26, 2026 | quiverquant.comQSCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247February 26, 2026 | globenewswire.comCERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsFebruary 17, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYNZ, ELUT, APLM, and SCYX Company DescriptionsApollomics NASDAQ:APLM$18.58 -0.28 (-1.46%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$18.58 0.00 (0.00%) As of 07/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.Elutia NASDAQ:ELUT$0.93 0.00 (-0.27%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.93 +0.00 (+0.43%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Mainz Biomed NASDAQ:MYNZ$1.08 -0.03 (-2.70%) As of 07/24/2026Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.SCYNEXIS NASDAQ:SCYX$3.73 -0.23 (-5.81%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$3.73 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
